Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nausea Rate with Bremelanotide Alone or with Zofran in Healthy Women
NCT03973047Phase 1Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bremelanotide in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Incidence of treatment-emergent nausea at 2 days. Started Jun 2019; status: completed.
02
Drugs
bremelanotide
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT03973047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973047.